• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Molecular markers associated with bone marrow clearance in AML and MDS

byMatthew Lin, MDandShaidah Deghan, MSc. MD
November 25, 2016
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. TP53 mutant status significantly associated with bone marrow blast clearance after treatment with decitabine in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).

Evidence Rating Level: 2 (good)
­

Study Rundown: AML and MDS are clonal myeloid neoplasms. Decitabine is a hypomethylating agent that promotes re-expression of tumor suppressor genes, and is commonly used as a single-agent therapy in treating AML and MDS. In this prospective cohort study, researchers evaluated whether molecular determinants such as mutation status, in adult patients age ≥60 with AML, relapsed AML or transfusion-dependent MDS, impact clinical response to 10-day decitabine treatment. Overall, they found that AML and MDS patients categorized as having unfavorable-risk cytogenetic profiles, TP53 mutations or both, had significant clinical responses and mutation clearance after decitabine treatment. However, the authors note that while single-therapy decitabine is not a cure for AML and MDS, as rapid selection of resistant subclones frequently occurs after decitabine treatment, this therapy may nonetheless become an important way of inducing clinical remission.

Click to read the study, published in NEJM

Relevant Reading: Decitabine in the treatment of acute myeloid leukemia in elderly patients

In-Depth [prospective cohort]: In this prospective cohort study, 116 patients received a 10-day course of decitabine on days 1-10 of a 28-day. 84 patients received decitabine on days 1-10 of a 28-day cycle (median of two cycles) at Washington University in St. Louis. Response criteria categories were used per the International Working Group for AML and MDS and bone marrow samples were collected on days 0, 10 and 28 of cycle 1. The overall response rate was 46% – 15 of the 116 (13%) patients achieved complete remission and 38 (33%) had bone marrow clearance with ≤5% blasts. Overall, 54 patients had enhanced exome sequencing performed on them. 40% of the sequenced patients who had a response that included complete remission, complete remission with incomplete count recovery or morphologic complete remission also had TP53 mutations (p < 0.001). Bone marrow blast clearance occurred in 29 of 43 (67%) patients with unfavorable-risk karyotype, 24 of 71 (34%) patients intermediate risk karyotype (p < 0.001). Clearance also occurred in 21 of 21 (100%) of patients with TP53 mutations vs. 32 of 78 (41%) patients with wild-type TP53 mutations (p < 0.001).

Image: PD

RELATED REPORTS

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myeloid leukemiamyelodysplastic syndrome
Previous Post

Palliative care likely to improve patient quality of life and reduce symptom burden

Next Post

Palliative care intervention improves quality of life during hospitalization for hematopoietic stem cell transplantation

RelatedReports

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy
Chronic Disease

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

May 13, 2022
#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia
StudyGraphics

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

November 27, 2021
#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates
StudyGraphics

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

September 30, 2021
#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation
StudyGraphics

#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation

August 12, 2021
Next Post
Palliative care intervention improves quality of life during hospitalization for hematopoietic stem cell transplantation

Palliative care intervention improves quality of life during hospitalization for hematopoietic stem cell transplantation

Contrast-enhanced computed tomography associated with high sensitivity to renal stone detection

Contrast-enhanced computed tomography associated with high sensitivity to renal stone detection

Physical toll observed among high-striving black adolescents from low-income families

Physical toll observed among high-striving black adolescents from low-income families

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Former professional football players may be at greater risk of chronic disease
  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options